Debra Stuurman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Debra Stuurman has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Wytske M. van Weerden
Department of Urology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
37 shared publications - Annelies Van Hemelryk
Department of Urology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
36 shared publications - Sigrun Erkens-Schulze
Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands
36 shared publications - Martin E. van Royen
Department of Pathology, Erasmus MC, 3015 GE Rotterdam, The Netherlands
35 shared publications - Wilma J. Teubel
Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands
35 shared publications - Ron H.J. Mathijssen
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
34 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Darolutamide and docetaxel pharmacokinetics in PC346C bearing mice, related to Figure 2A-C. A: Mean systemic darolutamide concentrations in PC346C bearing mice treated with darolutamide, with or without docetaxel (n=8 and n=9 per group, respectively) directly after oral darolutamide administration at treatment initiation (start), 2 weeks or 4 weeks after treatment initiation and at time of mouse sacrifice (end). B: Mean systemic docetaxel concentrations in PC346C bearing mice treated with docetaxel, with or without darolutamide (n=8 per group) directly after i.v. docetaxel administration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Darolutamide and docetaxel pharmacokinetics in PC346C bearing mice, related to Figure 2A-C. A: Mean systemic darolutamide concentrations in PC346C bearing mice treated with darolutamide, with or without docetaxel (n=8 and n=9 per group, respectively) directly after oral darolutamide administration at treatment initiation (start), 2 weeks or 4 weeks after treatment initiation and at time of mouse sacrifice (end). B: Mean systemic docetaxel concentrations in PC346C bearing mice treated with docetaxel, with or without darolutamide (n=8 per group) directly after i.v. docetaxel administration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in PC346C-Enzalutamide resistant cells. A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in PC346C-Enzalutamide resistant cells. A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Expression of the AR and its splice variants. GAPDH normalized expression of full length (A) and alternatively spliced AR (B) mRNA. In PC2416-DEC tumors, AR full length expression is 2.5 times higher compared to PC346C tumors, while AR splice variants have a 1.4 to 3.4 times higher expression in PC2416-DEC tumors compared to PC346C. Data adapted from Van Hemelryk et al. (13)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Expression of the AR and its splice variants. GAPDH normalized expression of full length (A) and alternatively spliced AR (B) mRNA. In PC2416-DEC tumors, AR full length expression is 2.5 times higher compared to PC346C tumors, while AR splice variants have a 1.4 to 3.4 times higher expression in PC2416-DEC tumors compared to PC346C. Data adapted from Van Hemelryk et al. (13)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in C4-2B4 and LNCaP. Dose-response curve with mean normalized viability (+/- SEM) of two (A-B) or three (C-D) separate experiments with technical triplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in C4-2B4 and LNCaP. Dose-response curve with mean normalized viability (+/- SEM) of two (A-B) or three (C-D) separate experiments with technical triplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in PC346C PDXOs. A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value. B: Logarithmic Combination Index (CI) plot for the combination of docetaxel and darolutamide, identifying synergistic (log(CI) < 0), additive (log(CI) = 0) or antagonistic (log(CI) > 0) effects. Fa: fractional effect. The combination index and corresponding degree of synergism or antagonism is indicated for each combination.(18)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in PC346C PDXOs. A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value. B: Logarithmic Combination Index (CI) plot for the combination of docetaxel and darolutamide, identifying synergistic (log(CI) < 0), additive (log(CI) = 0) or antagonistic (log(CI) > 0) effects. Fa: fractional effect. The combination index and corresponding degree of synergism or antagonism is indicated for each combination.(18)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Western blot of p27, PSA and AR in LNCaP cells after treatment as indicated for 24 hours. GAPDH was used as loading control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Western blot of p27, PSA and AR in LNCaP cells after treatment as indicated for 24 hours. GAPDH was used as loading control.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Darolutamide suppresses the AR in NMRI nu/nu male mice effectively and safely. A-B: 16 NMRI nu/nu male mice subcutaneously bearing a PC346C tumor were treated for 14 days with 200 mg/kg darolutamide orally daily (n=4), 100 mg/kg darolutamide orally daily (n=4), were castrated and received vehicle (n=4) or were sham-castrated and received vehicle (n=4). Mean of prostate and seminal vesicle weight with SD is shown. *: p < 0.05; **: p < 0.01. C: Bodyweight of mice treated with darolutamide was not different from mice treated with vehicle, while bodyweight loss of castrated mice reached up to 5%, before recovery after 14 days.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Darolutamide suppresses the AR in NMRI nu/nu male mice effectively and safely. A-B: 16 NMRI nu/nu male mice subcutaneously bearing a PC346C tumor were treated for 14 days with 200 mg/kg darolutamide orally daily (n=4), 100 mg/kg darolutamide orally daily (n=4), were castrated and received vehicle (n=4) or were sham-castrated and received vehicle (n=4). Mean of prostate and seminal vesicle weight with SD is shown. *: p < 0.05; **: p < 0.01. C: Bodyweight of mice treated with darolutamide was not different from mice treated with vehicle, while bodyweight loss of castrated mice reached up to 5%, before recovery after 14 days.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in VCaP PDXOs A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value. B: Logarithmic Combination Index (CI) plot for the combination of docetaxel and darolutamide, identifying synergistic (log(CI) < 0), additive (log(CI) = 0) or antagonistic (log(CI) > 0) effects. Fa: fractional effect. The combination index and corresponding degree of synergism or antagonism is indicated for each combination.(18)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Combination of docetaxel and darolutamide in VCaP PDXOs A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value. B: Logarithmic Combination Index (CI) plot for the combination of docetaxel and darolutamide, identifying synergistic (log(CI) < 0), additive (log(CI) = 0) or antagonistic (log(CI) > 0) effects. Fa: fractional effect. The combination index and corresponding degree of synergism or antagonism is indicated for each combination.(18)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Ki-67 staining of PC346C PDX tumor samples. Ki-67 staining of PC346C PDX tumors after eight days of treatment with darolutamide or vehicle and an i.v. injection of docetaxel or vehicle at day five. (n=4 per group, except for vehicle/vehicle with n=3)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
Ki-67 staining of PC346C PDX tumor samples. Ki-67 staining of PC346C PDX tumors after eight days of treatment with darolutamide or vehicle and an i.v. injection of docetaxel or vehicle at day five. (n=4 per group, except for vehicle/vehicle with n=3)